|
1
|
Litvinov SV, Balzar M, Winter MJ, et al:
Epithelial cell adhesion molecule (Ep-CAM) modulates cell-cell
interactions mediated by classic cadherins. J Cell Biol.
139:1337–1348. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Baeuerle PA and Gires O: EpCAM (CD326)
finding its role in cancer. Br J Cancer. 96:417–423. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Went PT, Lugli A, Meier S, et al: Frequent
EpCam protein expression in human carcinomas. Hum Pathol.
35:122–128. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Munz M, Baeuerle PA and Gires O: The
emerging role of EpCAM in cancer and stem cell signaling. Cancer
Res. 69:5627–5629. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Patriarca C, Macchi RM, Marschner AK and
Mellstedt H: Epithelial cell adhesion molecule expression (CD326)
in cancer: a short review. Cancer Treat Rev. 38:68–75. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Schmidt M, Scheulen ME, Dittrich C, et al:
An open-label, randomized phase II study of adecatumumab, a fully
human anti-EpCAM antibody, as monotherapy in patients with
metastatic breast cancer. Ann Oncol. 21:275–282. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Niedzwiecki D, Bertagnolli MM, Warren RS,
et al: Documenting the natural history of patients with resected
stage II adenocarcinoma of the colon after random assignment to
adjuvant treatment with edrecolomab or observation: results from
CALGB 9581. J Clin Oncol. 29:3146–3152. 2011. View Article : Google Scholar
|
|
8
|
Maetzel D, Denzel S, Mack B, et al:
Nuclear signalling by tumour-associated antigen EpCAM. Nat Cell
Biol. 11:162–171. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
9
|
Ralhan R, He HC, So AK, et al: Nuclear and
cytoplasmic accumulation of Ep-ICD is frequently detected in human
epithelial cancers. PLoS One. 5:e141302010. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Carpenter G and Red Brewer M: EpCAM:
another surface-to-nucleus missile. Cancer Cell. 15:165–166. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Schmalhofer O, Brabletz S and Brabletz T:
E-cadherin, beta-catenin, and ZEB1 in malignant progression of
cancer. Cancer Metastasis Rev. 28:151–166. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Polette M, Mestdagt M, Bindels S, et al:
Beta-catenin and ZO-1: shuttle molecules involved in tumor
invasion-associated epithelial-mesenchymal transition processes.
Cells Tissues Organs. 185:61–65. 2007. View Article : Google Scholar
|
|
13
|
Vincan E and Barker N: The upstream
components of the Wnt signalling pathway in the dynamic EMT and MET
associated with colorectal cancer progression. Clin Exp Metastasis.
25:657–663. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Paul S and Dey A: Wnt signaling and cancer
development: therapeutic implication. Neoplasma. 55:165–176.
2008.PubMed/NCBI
|
|
15
|
Khan SA, Thomas HC, Davidson BR and
Taylor-Robinson SD: Cholangiocarcinoma. Lancet. 366:1303–1314.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Blechacz B and Gores GJ:
Cholangiocarcinoma: advances in pathogenesis, diagnosis, and
treatment. Hepatology. 48:308–321. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
van der Gaag NA, Kloek JJ, de Bakker JK,
et al: Survival analysis and prognostic nomogram for patients
undergoing resection of extrahepatic cholangiocarcinoma. Ann Oncol.
23:2642–2649. 2012.PubMed/NCBI
|
|
18
|
Kim DG, Park SY, You KR, et al:
Establishment and characterization of chromosomal aberrations in
human cholangiocarcinoma cell lines by cross-species color banding.
Genes Chromosomes Cancer. 30:48–56. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Bae JS, Noh SJ, Jang KY, et al: Expression
and role of epithelial cell adhesion molecule in dysplastic nodule
and hepatocellular carcinoma. Int J Oncol. 41:2150–2158.
2012.PubMed/NCBI
|
|
20
|
Kwon CY, Kim KR, Choi HN, et al: The role
of serum response factor in hepatocellular carcinoma: Implications
for disease progression. Int J Oncol. 37:837–844. 2010.PubMed/NCBI
|
|
21
|
Litvinov SV, Velders MP, Bakker HA,
Fleuren GJ and Warnaar SO: Ep-CAM: a human epithelial antigen is a
homophilic cell-cell adhesion molecule. J Cell Biol. 125:437–446.
1994. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
van der Gun BT, Melchers LJ, Ruiters MH,
de Leij LF, McLaughlin PM and Rots MG: EpCAM in carcinogenesis: the
good, the bad or the ugly. Carcinogenesis. 31:1913–1921.
2010.PubMed/NCBI
|
|
23
|
Trzpis M, McLaughlin PM, de Leij LM and
Harmsen MC: Epithelial cell adhesion molecule: more than a
carcinoma marker and adhesion molecule. Am J Pathol. 171:386–395.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Ralhan R, Cao J, Lim T, Macmillan C,
Freeman JL and Walfish PG: EpCAM nuclear localization identifies
aggressive thyroid cancer and is a marker for poor prognosis. BMC
Cancer. 10:3312010. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Warneke VS, Behrens HM, Haag J, et al:
Members of the EpCAM signalling pathway are expressed in gastric
cancer tissue and are correlated with patient prognosis. Br J
Cancer. 109:2217–2227. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Fong D, Moser P, Kasal A, et al: Loss of
membranous expression of the intracellular domain of EpCAM is a
frequent event and predicts poor survival in patients with
pancreatic cancer. Histopathology. 64:683–692. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Lin CW, Liao MY, Lin WW, Wang YP, Lu TY
and Wu HC: Epithelial cell adhesion molecule regulates tumor
initiation and tumorigenesis via activating reprogramming factors
and epithelial-mesenchymal transition gene expression in colon
cancer. J Biol Chem. 287:39449–39459. 2012. View Article : Google Scholar
|
|
28
|
Gosens MJ, van Kempen LC, van de Velde CJ,
van Krieken JH and Nagtegaal ID: Loss of membranous Ep-CAM in
budding colorectal carcinoma cells. Mod Pathol. 20:221–232. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Kessenbrock K, Plaks V and Werb Z: Matrix
metalloproteinases: regulators of the tumor microenvironment. Cell.
141:52–67. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Denzel S, Mack B, Eggert C, et al: MMP7 is
a target of the tumour-associated antigen EpCAM. Int J Exp Pathol.
93:341–353. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Litvinov SV, van Driel W, van Rhijn CM, et
al: Expression of Ep-CAM in cervical squamous epithelia correlates
with an increased proliferation and the disappearance of markers
for terminal differentiation. Am J Pathol. 148:865–875. 1996.
|
|
32
|
Chaves-Pérez A, Mack B, Maetzel D, et al:
EpCAM regulates cell cycle progression via control of cyclin D1
expression. Oncogene. 32:641–650. 2013.
|
|
33
|
Osta WA, Chen Y, Mikhitarian K, et al:
EpCAM is overexpressed in breast cancer and is a potential target
for breast cancer gene therapy. Cancer Res. 64:5818–5824. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Yamashita T, Ji J, Budhu A, et al:
EpCAM-positive hepatocellular carcinoma cells are tumor-initiating
cells with stem/progenitor cell features. Gastroenterology.
136:1012–1024. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Münz M, Kieu C, Mack B, Schmitt B, Zeidler
R and Gires O: The carcinoma-associated antigen EpCAM upregulates
c-myc and induces cell proliferation. Oncogene. 23:5748–5758.
2004.PubMed/NCBI
|
